Parallel Bio
YC S21San Francisco, US · Founded 2021 · 20 employees · 6 known investors
Parallel Bio develops human immune organoids and computational tools to predict drug efficacy across diverse patient populations, replacing animal testing in drug discovery. The company aims to accelerate pharmaceutical development and reduce clinical trial failure rates through human-first biological prediction models.
Founders & leadership· Y Combinator alumni (S21)
Investors · 6
In the news
- Accelerating Organoid Adoption Set to Transform Cancer Drugsgenengnews.com · 2026
- Parallel Bio's embraces in-house drug development as FDA backs animal testing alternativesrdworldonline.com · 2026
- Why a human-first approach is the future of drug discovery | Drug Discovery Newsdrugdiscoverynews.com · 2025
- How AI And Mini-Organs Could Replace Testing Drugs On Animalsforbes.com · 2025
- Parallel Bio secures $21m to advance human-first drug discovery - Drug Discovery World (DDW)ddw-online.com · 2025
- Parallel Bio's $21M in Series A will drive aim to cut $2B and 9 years from drug developmentdrugdiscoverytrends.com · 2025
- Parallel Bio Raises $21M in Series A Fundingfinsmes.com · 2025
- Parallel Bio Secures $21 Million in Series A to Advance Human-First Drug Discoverybusinesswire.com · 2025